Comparison of the incidence of opacification of Hydroview hydrogel intraocular lenses with the ophthalmic viscosurgical device used during surgery.
OBJECTIVE
To determine the effect of intraoperative ophthalmic viscosurgical devices (OVDs) on late opacification of the Hydroview hydrogel intraocular lens (IOL) (Bausch & Lomb Surgical).


METHODS
Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.


METHODS
A retrospective study of 949 cases of Hydroview IOL implantations from February 1998 to September 2000 was conducted. Of the 949 implantations, 462 were performed by 1 surgeon (J.H.S.) using Viscoat (sodium chondroitin sulfate 4.0%-sodium hyaluronate 3.0%) and 487 were performed by a second surgeon (W.A.N.) using Biolon (sodium hyaluronate 1.0%). Surgical techniques were identical with the exception of surgeon OVD preference. The number of IOLs opacifying and requiring explantation was determined in each group.


RESULTS
Seventy-one Hydroview IOLs had surface calcification deposits that presented a mean of 39 months postoperatively. Twenty-two IOLs opacified sufficiently to warrant a recommendation of IOL explantation; 20 IOLs were explanted, and 2 surgeries were cancelled due to death or disability. In all cases of opacification, Viscoat had been used intraoperatively. This represented a 15.4% incidence of opacification in the Viscoat group, with 31.0% cases severe enough to warrant a recommendation of explantation.


CONCLUSIONS
The results suggest that the intraoperative use of Viscoat has a facilitating role in the development of late calcification and opacification of the Hydroview IOL.
Sher
Jeffrey H
JH
Department of Eye Medicine and Surgery, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Gooi
Patrick
P
Dubinski
William
W
Brownstein
Seymour
S
El-Defrawy
Sherif
S
Nash
Wesley A
WA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002114:Calcinosis / Q000209:etiology; D002807:Chondroitin / Q000009:adverse effects*; D002809:Chondroitin Sulfates; D020878:Device Removal; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000009:adverse effects*; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D015994:Incidence; D019654:Lens Implantation, Intraocular; D007910:Lenses, Intraocular; D008297:Male; D008875:Middle Aged; D011475:Prosthesis Failure; D012086:Reoperation; D012189:Retrospective Studies
D004338:Drug Combinations; C501944:chondroitin sulfate, sodium hyaluronate drug combination; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D006820:Hyaluronic Acid; D002807:Chondroitin; D002809:Chondroitin Sulfates